Rapid weight loss, particularly when exceeding 1.5 kg (3.3 pounds) per week, promotes cholesterol supersaturation in bile and crystal formation
It specifically flags a history of pancreatitis, medullary thyroid cancer, multiple endocrine neoplasia syndrome Type 2, or Type 1 diabetes as reasons a provider may recommend against them, though the exact contraindications and warnings vary by specific drug
Some patients may transition safely under medical supervision, while others may experience increased appetite or weight regain if medications are stopped too quickly
Different experiments may use different concentrations and methods of application depending on what results are expected from them
The results of the Evaluation of LIXisenatide in Acute coronary syndrome (ELIXA) trial, the first cardiovascular outcomes trial for the short-acting GLP-1 RA lixisenatide, were also published recently [52]